NASDAQ · DCTH
Healthcare · Medical - Devices
$14.40
Up+$0.42 (+2.92%)
Updated Nov 5, 2026, 12:35 AM
SID Score
5.7/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · DCTH
1M range · 20 trading sessions · Daily adjusted prices
Prices through Nov 3, 2026
DCTH closed at $14.40 after 20 trading sessions, down 6.37% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 3, 2026 | $14.25 | $14.53 | $14.20 | $14.40 | 387.61K |
| Nov 2, 2026 | $14.09 | $14.615 | $14.03 | $14.29 | 364.89K |
| Oct 30, 2026 | $14.64 | $15.24 | $13.91 | $14.04 | 427.35K |
| Oct 29, 2026 | $14.97 | $15.20 | $14.535 | $14.64 | 239.25K |
| Oct 28, 2026 | $14.74 | $14.89 | $14.65 | $14.86 | 315.2K |
| Oct 27, 2026 | $14.56 | $14.84 | $14.48 | $14.75 | 245.07K |
| Oct 26, 2026 | $14.41 | $14.72 | $14.32 | $14.51 | 232.86K |
| Oct 23, 2026 | $14.73 | $14.73 | $14.33 | $14.42 | 326.48K |
| Oct 22, 2026 | $14.59 | $14.875 | $14.58 | $14.75 | 401.18K |
| Oct 21, 2026 | $14.75 | $14.91 | $14.57 | $14.70 | 277.76K |
| Oct 20, 2026 | $14.46 | $14.93 | $14.405 | $14.76 | 294.23K |
| Oct 19, 2026 | $14.16 | $14.52 | $14.0836 | $14.37 | 300.21K |
| Oct 16, 2026 | $14.81 | $14.83 | $14.00 | $14.08 | 384.01K |
| Oct 15, 2026 | $14.70 | $14.965 | $14.62 | $14.81 | 214.87K |
| Oct 14, 2026 | $15.24 | $15.41 | $14.695 | $14.72 | 231.96K |
| Oct 13, 2026 | $15.57 | $15.77 | $15.295 | $15.32 | 251.36K |
| Oct 12, 2026 | $15.36 | $15.75 | $15.295 | $15.67 | 207.46K |
| Oct 9, 2026 | $15.07 | $15.40 | $14.945 | $15.36 | 190.11K |
| Oct 8, 2026 | $15.22 | $15.23 | $14.52 | $15.04 | 416.34K |
| Oct 7, 2026 | $15.27 | $15.82 | $15.27 | $15.38 | 263.08K |
The latest Smart Investors Daily articles mentioning DCTH.
Company
Market Activity
Research & News
DCTH research
Company profile and research snapshot.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 7, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 6, 2026 | BTIG | Buy | — |
| Feb 26, 2026 | BTIG | Buy | — |
| Jan 9, 2026 | HC Wainwright & Co. | Buy | — |
| Nov 5, 2025 | Stephens & Co. | Overweight | — |
No generated briefing is available yet.
Yahoo · Oct 27, 2026
QUEENSBURY, N.Y., October 27, 2026--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that management will be attending the following investor conferences:
Yahoo · Oct 26, 2026
QUEENSBURY, N.Y., October 26, 2026--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on November 9, 2026, at 8:30 AM Eastern Time to discuss results for its third quarter ended September 30, 2026.
Yahoo · Oct 19, 2026
QUEENSBURY, N.Y., October 19, 2026--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced presentations related to its clinical development programs at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23–27 in Madrid, Spain. The Company also highlighted the publication of an independent, investigator-led analysis of percutaneous hepatic perfusion (PHP) w
Benzinga · Oct 19, 2026
Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced presentations related to its clinical development
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning DCTH.
